Diabetes affects 9% of the United States population and approximately one-third of these patients experience chronic neuropathic pain, commonly referred to as painful diabetic neuropathy (PDN). PDN is difficult to manage as analgesic treatments are only effective in a small subset of PDN patients. The development of analgesics for pain associated with diabetes, in particular type 2 diabetes, is stalled by our incomplete understanding of the underlying mechanisms of PDN. An important new clue comes from the recent finding that methylglyoxal (MG), a highly reactive dicarbonyl product of glycolysis that accumulates with hyperglycemia, is particularly high in patients with PDN. MG causes non-enzymatic glycation of proteins. The resulting protein adducts, or advanced glycation end products (MG-AGEs), are toxic and contribute to diabetic complications including PDN. Our central hypothesis is that elevated MG in type 2 diabetes causes pain and that this can be alleviated with new classes of drugs targeting MG itself, TRPA1, AC1, Epac, and PPAR?. To test the hypothesis that MG drives neuropathic pain (PDN) in type 2 diabetes, Specific Aim 1 will first determine whether elevations in MG and its metabolizing enzyme, Glyoxalase-1, occur in pain processing tissues in the hereditary Leprdb/db (db/db) mouse and Zucker Diabetic Fatty (ZDF) rat models of type 2 diabetes. We then ask whether a promising new class of MG-scavenging peptides will alleviate affective pain and spinal pain transmission. Our preliminary data indicate that genetic deletion or pharmacological inhibition of TRPA1, a glycation target of MG, blocks MG-induced pain. Indeed, TRPA1 is a leading target for the development of new analgesics for chronic pain, but has not been tested in models of type 2 PDN. To fill this gap, Specific Aim 2 will test the hypothesis that TRPA1 antagonists reduce affective pain and spinal pain transmission in db/db mice and ZDF rats. Consequent to TRPA1 channel opening (e.g. by MG), the resulting Ca2+ influx into the cell leads to the activation of Ca2+-sensitive proteins, which includes adenylyl cyclase I (AC1). Our data indicate that selective inhibition of AC1 with NB001 blocks type 2 PDN. AC1 generates the intracellular second messenger, cAMP, which targets not only protein kinase A but also exchange protein directly activated by cAMP (Epac).
Specific Aim 3 will use novel Epac1 and Epac2 small molecule inhibitors to determine which of these targets drive PDN. Among the 33 original research articles, reviews, and a book published during the previous funding cycle (22 with the PI as first or senior author), our Progress includes the discovery that pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR?) agonist that is FDA- approved to treat diabetes, acts at dorsal horn neurons to inhibit the chronic pain associated with cutaneous inflammation and traumatic nerve injury. Our new data indicate additional efficacy in PDN and MG-induced pain, with surprisingly robust analgesic effects in females.
Specific Aim 4 proposes to study PPAR? mechanism of action in db/db and ZDF, with a new focus on sex differences in spinal nociceptive transmission.

Public Health Relevance

Diabetes affects almost 9% of the United States population and approximately one-third of these patients experience chronic pain, termed painful diabetic neuropathy (PDN). Commercial analgesic drugs do not work well in patients with advanced PDN, yielding pain relief in less than 50% of patients, and of those, the pain relief is less than 50%. This project explores a new mechanism of PDN that is driven by the toxic by-product of high glucose ? methylglyoxal (MG) ? and evaluates four promising new drug targets (MG itself, TRPA1, AC1, and PPAR?) towards a new pharmacotherapy for this debilitating condition.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS062306-11
Application #
9894861
Study Section
Somatosensory and Chemosensory Systems Study Section (SCS)
Program Officer
Mohapatra, Durga Prasanna
Project Start
2008-12-18
Project End
2022-01-31
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
11
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Anesthesiology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Doolen, Suzanne; Iannitti, Tommaso; Donahue, Renee R et al. (2018) Fingolimod reduces neuropathic pain behaviors in a mouse model of multiple sclerosis by a sphingosine-1 phosphate receptor 1-dependent inhibition of central sensitization in the dorsal horn. Pain 159:224-238
Cooper, Andrew H; Brightwell, Jennifer J; Hedden, Naomi S et al. (2018) The left central nucleus of the amygdala contributes to mechanical allodynia and hyperalgesia following right-sided peripheral nerve injury. Neurosci Lett 684:187-192
Griggs, Ryan B; Laird, Don E; Donahue, Renee R et al. (2017) Methylglyoxal Requires AC1 and TRPA1 to Produce Pain and Spinal Neuron Activation. Front Neurosci 11:679
Harte, Steven E; Meyers, Jessica B; Donahue, Renee R et al. (2016) Mechanical Conflict System: A Novel Operant Method for the Assessment of Nociceptive Behavior. PLoS One 11:e0150164
Kaushal, R; Taylor, B K; Jamal, A B et al. (2016) GABA-A receptor activity in the noradrenergic locus coeruleus drives trigeminal neuropathic pain in the rat; contribution of NA?1 receptors in the medial prefrontal cortex. Neuroscience 334:148-159
Griggs, Ryan B; Donahue, Renee R; Adkins, Braxton G et al. (2016) Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes. J Pain 17:359-73
Fu, Weisi; Taylor, Bradley K (2015) Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Neurosci Lett 595:1-6
Griggs, Ryan B; Donahue, Renee R; Morgenweck, Jenny et al. (2015) Pioglitazone rapidly reduces neuropathic pain through astrocyte and nongenomic PPAR? mechanisms. Pain 156:469-82
Maimaiti, Shaniya; DeMoll, Chris; Anderson, Katie L et al. (2015) Short-lived diabetes in the young-adult ZDF rat does not exacerbate neuronal Ca(2+) biomarkers of aging. Brain Res 1621:214-21
Taylor, Bradley K (2015) Resolvin D1: A New Path to Unleash the Analgesic Potential of Peroxisome Proliferator-activated Receptor-? for Postoperative Pain in Patients with Diabetes. Anesthesiology 123:1231-2

Showing the most recent 10 out of 23 publications